MNOV MEDICINOVA INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1226616 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY12.2%
TTM EPS YoY16.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,232.2%
Net margin-1,127.0%
FCF margin-1,047.7%
EBITDA margin-1,230.3%
Returns
ROE-24.8%
ROA-22.7%
ROIC (approx.)-78.4%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets9.2%
Debt / equity0.00x
Current ratio8.75x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-1.6%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $409,657 | — | $1.00M | — | $4.04M |
| R&D expense | $6.70M | $6.80M | $5.30M | $8.70M | $8.10M |
| SG&A expense | $6.16M | $5.48M | $5.24M | $5.48M | $5.72M |
| Operating income | -$13.28M | -$12.68M | -$9.90M | -$14.63M | -$10.22M |
| Pretax income | -$11.99M | -$11.04M | -$8.57M | -$14.07M | -$10.13M |
| Income tax | $5,994 | $5,537 | $3,047 | $2,822 | $2,568 |
| Net income | -$12.00M | -$11.05M | -$8.57M | -$14.07M | -$10.13M |
| EBITDA | -$13.26M | -$12.65M | -$9.88M | -$14.61M | -$10.19M |
| EPS (basic) | -0.24 | -0.23 | -0.17 | -0.29 | -0.21 |
| EPS (diluted) | -0.24 | -0.23 | -0.17 | -0.29 | -0.21 |
| Weighted avg. shares (diluted) | 49.06M | 49.05M | 49.05M | 49.05M | 48.60M |
| Balance sheet | |||||
| Cash & equivalents | $30.81M | $40.36M | $51.00M | $18.51M | $71.43M |
| Short-term investments | — | — | — | $39.98M | — |
| Receivables | $0 | $0 | — | — | — |
| Current assets | $30.99M | $41.07M | $51.17M | $58.99M | $72.01M |
| PP&E, net | $8,340 | $25,507 | $45,800 | $45,269 | $57,565 |
| Goodwill | $9.60M | $9.60M | $9.60M | $9.60M | $9.60M |
| Total assets | $45.60M | $55.88M | $66.27M | $74.15M | $87.41M |
| Current liabilities | $3.80M | $2.96M | $3.28M | $3.19M | $2.83M |
| Total liabilities | $4.02M | $3.37M | $3.89M | $3.91M | $3.73M |
| Shareholders' equity | $41.59M | $52.50M | $62.38M | $70.24M | $83.68M |
| Shares outstanding | 49.22M | 49.05M | 49.05M | 49.05M | 49.04M |
| Cash flow statement | |||||
| Operating cash flow | -$9.81M | -$10.64M | -$7.43M | -$12.91M | -$9.38M |
| Capital expenditure | $2,899 | $895 | $21,299 | $5,010 | $28,732 |
| Free cash flow | -$9.81M | -$10.64M | -$7.45M | -$12.92M | -$9.41M |
| Investing cash flow | -$2,899 | -$697 | $39.91M | -$40.01M | -$28,732 |
| Financing cash flow | $244,018 | $0 | — | $7,920 | $20.78M |
| Depreciation & amortization | $20,099 | $21,077 | $20,295 | $17,707 | $26,149 |
| Stock-based compensation | $829,095 | $1.19M | $710,710 | $642,522 | $1.72M |
Free plan shows the latest 5 periods; Pro shows all 26 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.